Navigation Links
Despite Patent Expiries of Leading Therapies, New Product Launches Will Drive a $4.6 Billion Increase in the Coronary Heart Disease Market
Date:3/24/2009

Growth Will be Driven by Drugs from Eli Lilly/Daiichi Sankyo, AstraZeneca, and Schering-Plough, According to a New Report from Decision Resources

WALTHAM, Mass., March 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the patent expiries by 2012 of the two sales-leading therapies, new product launches will drive an increase of $4.6 billion in the overall coronary heart disease market by 2017.

The new Pharmacor report entitled Coronary Heart Disease finds that the market to treat the disease will grow from $14.8 billion in 2007 to $19.4 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Growth will be driven by the launches of Eli Lilly/Daiichi Sankyo's Efient/Effient, AstraZeneca's Brilinta and Schering-Plough's SCH-530348 as well as the introduction of two new CETP inhibitors from Roche/Japan Tobacco and Merck.

Despite the patent expiry of the two sales-leading coronary heart disease therapies by 2012 -- Sanofi-Aventis/Bristol-Myers Squibb's Plavix/Iscover and Pfizer's Lipitor -- the market entry of fixed-dose combinations with agents such as Abbott's Tricor/TriLipix, Solvay's Lipanthyl and Abbott's Niaspan will also offset the negative impact of generic erosion, according to the report.

"Cardiologists' approach to coronary heart disease therapy has experienced a remarkable international convergence as optimal drug treatment for post-myocardial infarction -- the condition that accounts for more than 70 percent of coronary heart disease market sales -- now consists of two antiplatelet agents, including aspirin, a statin, an ACE inhibitor and a beta blocker," said Decision Resources Therapeutic Area Director Nikhil Mehta. "Multidrug therapy has also become routine in the treatment of stable angina. The arrival of novel agents will be welcomed by clinicians, particularly for high-risk patients, but some of these therapies could face market access and compliance hurdles."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                         Decision Resources, Inc.
    Christopher Comfort                        Elizabeth Marshall
    781-296-2597                               781-296-2563
    ccomfort@dresources.com                    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hagerstown Cosmetic Surgeon Weathers the Current Economic Storm Despite the Sharp Decline in the Number of Cosmetic Surgeries Performed Nationwide
2. The Center for Plastic Surgery in Washington, DC Survives the Economy Despite Nationwide Data Reported by ASAPS
3. Life Sciences Quality Managers Seek to Expand Compliance Initiatives Despite Economic Pressures
4. Georgia Metal Finisher Expands Despite Struggling Economy
5. Sexual health promotion is low among people with serious mental illnesses, despite higher risk
6. Code Pink Boot Camp Thrives Despite Rough Economy
7. State Health Reforms Progress Despite Ailing Economy
8. OrthoSynetics(TM) Same Practice New Contracts and Consults Growing Despite Economic Downturn
9. Americans Continue Eating Nutritious and Convenient Snacks Despite Tough Economic Times
10. Photos: Despite Widespread Awareness, Most Women Still Dont Feel at Risk for Cervical Cancer
11. Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Children ... to more adverse experiences than children in the general population. That’s because foster ... neglect or other family challenges. While no fault of their own, youth who ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
(Date:4/28/2017)... New York, New York (PRWEB) , ... April ... ... of high-quality anti-aging skincare and advanced nutraceutical supplements, through its Nova ... fast-absorbing cream provides the hydrating benefits of a moisturizer with the power of ...
(Date:4/27/2017)... PHILADELPHIA and DENVER (PRWEB) , ... April 27, ... ... Jewish Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an ... Institute is enabled by the continuing support of the Jane and Leonard Korman ...
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, Christine Collins ... the Year for her extraordinary compassion and lifelong dedication to serve others. Since ... caregivers for the prestigious award each year – identifying a CAREGiver who has ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... YORK , April 19, 2017 The Mobile ... to showcase a healthy CAGR during the forecast period ... type in the global digital mobile X-Ray devices market, which ... Mn in 2017, expanding at a CAGR of 7% over ... absolute $ opportunity of more than US$ 100 Mn in ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
Breaking Medicine Technology: